GHK-Cu is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II)-tripeptide complex | One peptide ligand with one coordinated metal centre |
| Peptide sequence | Gly-His-Lys | Three residues written in one-letter notation |
| Free peptide mass | 340.4 g/mol | Metal-free GHK; the complex has a higher mass |
| Appearance | Blue to violet solid or solution | Colour originates from copper d orbital transitions |
| Storage | Desiccated, -20 °C, protected from light | Dry powder is more stable than dissolved material |
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Ohmefentanyl (also known as β-hydroxy-3-methylfentanyl, OMF and RTI-4614-4) is an extremely potent opioid analgesic drug which selectively binds to the μ-opioid receptor. There are eight possible stereoisomers of ohmefentanyl. These stereoisomers are among the most potent μ-opioid receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which are only legally used for tranquilizing large animals such as elephants in veterinary medicine. In mouse studies, the most active stereoisomer, 3R,4S,βS-ohmefentanyl, was 28 times more powerful as a painkiller than fentanyl, the chemical from which it is derived, and 6300 times more powerful than morphine. Ohmefentanyl has three stereogenic centers and eight stereoisomers, which are named F9201–F9208. Researchers are studying the different pharmaceutical properties of these isomers. The 4″-fluoro analogue (i.e., substituted on the phenethyl ring) of the 3R,4S,βS isomer of ohmefentanyl is one of the most potent opioid agonists yet discovered, possessing an analgesic potency approximately 18,000 times that of morphine. Other analogues with potency higher than that of ohmefentanyl itself include the 2′-fluoro derivative (i.e., substituted on the aniline phenyl ring), and derivatives where the N-propionyl group was replaced by N-methoxyacetyl or 2-furamide groups, or a carboethoxy group is added to the 4-position of the piperidine ring. The latter is listed as being up to 30,000 times more potent than morphine.
=== Distribution === The apparent oral volume of distribution (VSS/F) at steady state of (R)-bicalutamide with oral administration of a single 5 to 80 mg dose of (R)-bicalutamide in a novel solid dispersion with a polymeric matrix of hydroxypropyl methylcellulose phthalate (HP55S) (also known as (R)-bicalutamide/HP55S) ranges from 22.53 ± 3.71 L to 25.38 ± 2.69 L. Bicalutamide is highly protein-bound (96.1% for racemic bicalutamide, 99.6% for (R)-bicalutamide), mainly to albumin. It has negligible affinity for SHBG and no affinity for corticosteroid-binding globulin. The tissue distribution of bicalutamide is not well-characterized. However, it has been reported that distribution studies with bicalutamide have shown that preferential (i.e., tissue-selective) accumulation in anabolic (e.g., muscle) tissues does not occur. There are no available data on hepatic bicalutamide concentrations in humans, but a rat study found that oral bicalutamide treatment resulted in 4-fold higher concentrations of the drug in the liver relative to plasma (a common finding with orally administered drugs, due to transfer through the hepatic portal system prior to reaching circulation). In men receiving 150 mg/day bicalutamide, concentrations of (R)-bicalutamide in semen were 4.9 μg/mL (11 μmol/L), and the amount of the drug that could potentially be delivered to a female partner during sexual intercourse is regarded as low (estimated at 0.3 μg/kg) and below the amount that is required to induce changes in the offspring of laboratory animals.
==== Consensus paper ==== In 2013 the E.S.PKU delegates launched a paper describing the needs for a better and equal treatment across Europe. This paper subsequently lead to the first European Guidelines for Phenylketonuria.
Sources: en.wikipedia.org
== Powers and abilities == Major Force is coated with the same Dilustel alien alloy that covers Captain Atom. As a result, he also can access the Quantum Field and use its energies for a variety of powers. Cracking or rupturing his Dilustel skin causes Major Force to leak radiation at an uncontrollable rate, to which he runs the risk of atomic detonation. Major Force can project blasts of dark matter and shape the energy into various forms. He initially lacked the ability to fly, but rather leapt great distances or traveled on ramps made of dark matter. Major Force is also able to convert whatever force he comes in contact with, be it matter or energy, into solid dark matter. Major Force possesses immense strength and durability, around the same level as Captain Atom and Superman. Major Force lacks the need for physical sustenance thanks to the Dilustel's connection to the Q-Field, allowing to survive indefinitely without need to eat, sleep, breath or rest, and survive in the vacuum of space. Due to his nature as pure energy, Major Force is functionally immortal. Clifford Zmeck is a military-trained United States Air Force operative. He has vast military connections with the government, Checkmate, Task Force X, and Quorum.
As of 2017, Canada had hundreds of acres of large-scale commercial hydroponic greenhouses, producing tomatoes, peppers and cucumbers. Due to technological advancements within the industry and numerous economic factors, the global hydroponics market is forecast to grow from US$226.45 million in 2016 to US$724.87 million by 2023.
set up a laboratory in the kitchen and woodshed of an old house in Washington near the area now occupied by buildings of the Department of Agriculture and there completed their researches on butter. This was the first dairy products research laboratory in Washington. Lore Rogers completed his first publications on butter. About this time he was elected to the Society of American Bacteriologists and in Washington married Beatrice Oberly, who was employed as bureau librarian. "Fishy Flavor in Butter" and "The Influence of Acidity of Cream on the Flavor of Butter" were published next. In 1909 the Dairy Research Laboratories were finally created and placed under the direction of Lore Rogers. His son, John Oberly Rogers, was born the same year. In 1911 he was selected as an official delegate representing the United States at the International Dairy Congress meeting at Stockholm. A publication on the spoiling of butter was published by the United States Department of Agriculture. By 1914 he was developing a procedure for preserving bacterial cultures by removing gas while in their frozen state. A few years later the United States Army would adopt the technique in the preparation of typhoid vaccines during World War I. In 1916 Lore Rogers became an advisory editor of the Journal of Bacteriology. A year later he was secretary of the Washington Branch of the Society of American Bacteriologists. In 1920 and 1921 he published articles on the manufacture of sweetened condensed milk and evaporated milk. In 1920 and 1922 he served as president of the American Society of Bacteriologists.
Sources: en.wikipedia.org
=== Economic === As a result of the fighting, Swiss International Air Lines and Lufthansa suspended flights to Beirut, while Lebanon's flag carrier Middle East Airlines relocated five of its 24 aircraft to Istanbul as a precaution. Australia, Canada, France, Germany, Spain and the United Kingdom advised against travelling to Lebanon, whilst the British embassy withdrew family members of its staff.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
== Warnings/Precautions == Pancreatitis has been reported in clinical trials, do not continue usage if any pancreatitis has been spotted or confirmed, other therapies should be considered in patients with a prior history of pancreatitis Hypoglycemia has been noted when used in combination with an insulin secretagogue or insulin, consider lowering the usage of insulin in order to reduce the risk of hypoglycemia Hypersensitivity reactions such as anaphylactic reactions and angioedema have occurred; in this case discontinue Trulicity/dulaglutide and seek medical advice Acute kidney injury, monitor the renal function in patients with renal impairment and report severe gastrointestinal reactions Severe gastrointestinal disease, as usage may sometimes be associated with severe gastrointestinal reactions. (Source)
In ruling on the 1986 Huanchaca case involving the slaying of a leading Bolivian scientist, his pilot, and a guide, the Third Criminal Court of Santa Cruz returned a guilty verdict in April 1988 against ten Brazilians and a Colombian, in addition to a Bolivian thought to be dead. The court, however, dismissed charges against five other Bolivian suspects, including several well-known drug traffickers. The freeing of two of the suspects by the Santa Cruz judges prompted the Supreme Court of Justice to demand the resignations of the entire Santa Cruz judiciary because of its leniency toward drug traffickers. Four Santa Cruz judges were dismissed because of irregularities in the Huanchaca case, which in early 1989 remained at an impasse, under advisement in the Supreme Court of Justice. Drug kingpin Roberto Suárez Gómez was arrested in 1988. Under the 1988 Antinarcotics Law, the Judicial Police must report antinarcotics operations to the closest Special Antinarcotics Force district within forty-eight hours. The law also called for the creation of three-judge Special NarcoticsControl Courts or tribunals (Juzgados Especiales de Narcotráfico) with broad responsibilities. In early 1989, the Supreme Court of Justice began appointing judges and lawyers to serve on the new tribunals, two of which began functioning as tribunals of first instance in narcotics-related cases, with jurisdiction for the judicial districts of La Paz, Cochabamba, Santa Cruz, and Beni.
Sources: en.wikipedia.org
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.
The three letters are the standard one-letter codes for glycine, histidine, and lysine. The suffix -Cu indicates the coordinated copper ion. Cosmetic ingredient lists often use the alternative name copper tripeptide-1 for the same complex.
No. Free GHK is the peptide alone, while GHK-Cu contains a bound copper atom. The two differ in colour, charge, and binding behaviour, so any study that measures copper delivery must state which form was used.
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.